BioSyent Inc.

BioSyent Inc. is a specialized pharmaceutical enterprise operating both within Canada and internationally. The company is actively involved in identifying, obtaining, developing, and commercializing a diverse portfolio of pharmaceutical and health-related products. Among its offerings are iron supplements such as FeraMAX 150, FeraMAX Powder (a water-soluble oral iron solution promoting red blood cell formation), and FeraMAX Pd Therapeutic 150, all designed to prevent and manage iron deficiency anemia. BioSyent also provides Cathejell, utilized for surface anesthesia and lubrication during various medical procedures including cystoscopy, catheterization, endoscopy, and tracheal intubation, as well as for symptomatic relief of pain associated with cystitis and urethritis. Other key products include RepaGyn, a vaginal suppository aimed at healing vaginal mucosa and alleviating dryness caused by factors like menopause, stress, and chemotherapy, and Proktis-M, a rectal suppository supporting the healing of the anal and rectal areas. Furthermore, its lineup features Combogesic for reducing moderate acute pain and fever in adults, Protect-It, a non-chemical, food-safe grain insecticide used to prevent insect infestations in stored grains, and Tibella, a hormone replacement therapy addressing vasomotor symptoms stemming from estrogen deficiency. The company distributes its products through wholesalers and retail pharmacy chains. Headquartered in Mississauga, Canada, BioSyent Inc. was incorporated in 2006, having previously operated as Hedley Technologies Inc. before rebranding in June 2006 to emphasize its strategic focus on the pharmaceutical sector.

BioSyent Inc. trades as RX.V on TSXV. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in CAD.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $43.05M of revenue and $9.01M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

BioSyent Inc. can be compared against peers such as BioNxt Solutions Inc., Cardiol Therapeutics Inc., Decibel Cannabis Company Inc., Grown Rogue International Inc., Jushi Holdings Inc., Cannara Biotech Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $158.88M, beta of 0.64, and return on equity of +21.7%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

RX.V currently shows total debt of $841,104 and beta of 0.64. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.biosyent.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.